메뉴 건너뛰기




Volumn 33, Issue 8, 2012, Pages 1591-1598

Serial CSF sampling in Alzheimer's disease: Specific versus non-specific markers

Author keywords

Alzheimer's disease; CSF biomarkers; Longitudinal

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; ISOPROSTANE; NEUROFILAMENT PROTEIN; TAU PROTEIN; THREONINE;

EID: 84861910849     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.05.013     Document Type: Article
Times cited : (48)

References (37)
  • 2
    • 0141738373 scopus 로고    scopus 로고
    • CSF markers for incipient Alzheimer's disease
    • Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003, 2:605-613.
    • (2003) Lancet Neurol , vol.2 , pp. 605-613
    • Blennow, K.1    Hampel, H.2
  • 6
    • 33746642088 scopus 로고    scopus 로고
    • Usefulness of longitudinal measurements of beta-amyloid1-42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders
    • Bouwman F.H., van der Flier W.M., Schoonenboom N.S., van Elk E.J., Kok A., Scheltens P., Blankenstein M.A. Usefulness of longitudinal measurements of beta-amyloid1-42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders. Clin. Chem 2006, 52:1604-1606.
    • (2006) Clin. Chem , vol.52 , pp. 1604-1606
    • Bouwman, F.H.1    van der Flier, W.M.2    Schoonenboom, N.S.3    van Elk, E.J.4    Kok, A.5    Scheltens, P.6    Blankenstein, M.A.7
  • 10
    • 35648937101 scopus 로고    scopus 로고
    • Current state and future directions of neurochemical biomarkers for Alzheimer's disease
    • de Jong D., Kremer B.P., Olde Rikkert M.G., Verbeek M.M. Current state and future directions of neurochemical biomarkers for Alzheimer's disease. Clin. Chem. Lab Med 2007, 45:1421-1434.
    • (2007) Clin. Chem. Lab Med , vol.45 , pp. 1421-1434
    • de Jong, D.1    Kremer, B.P.2    Olde Rikkert, M.G.3    Verbeek, M.M.4
  • 13
    • 0028169925 scopus 로고
    • Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43)
    • Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13:45-53.
    • (1994) Neuron , vol.13 , pp. 45-53
    • Iwatsubo, T.1    Odaka, A.2    Suzuki, N.3    Mizusawa, H.4    Nukina, N.5    Ihara, Y.6
  • 15
    • 0033591203 scopus 로고    scopus 로고
    • Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease
    • Kanai M., Shizuka M., Urakami K., Matsubara E., Harigaya Y., Okamoto K., Shoji M. Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease. Neurosci Lett 1999, 267:65-68.
    • (1999) Neurosci Lett , vol.267 , pp. 65-68
    • Kanai, M.1    Shizuka, M.2    Urakami, K.3    Matsubara, E.4    Harigaya, Y.5    Okamoto, K.6    Shoji, M.7
  • 16
    • 37749036105 scopus 로고    scopus 로고
    • Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques
    • Kumar-Singh S. Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques. Genes Brain Behav 2008, 1(7 Suppl):67-82.
    • (2008) Genes Brain Behav , vol.1 , Issue.7 SUPPL , pp. 67-82
    • Kumar-Singh, S.1
  • 19
    • 0021271971 scopus 로고
    • Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
    • McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
    • (1984) Neurology , vol.34 , pp. 939-944
    • McKhann, G.1    Drachman, D.2    Folstein, M.3    Katzman, R.4    Price, D.5    Stadlan, E.M.6
  • 21
    • 33645084250 scopus 로고    scopus 로고
    • Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease
    • Montine T.J., Quinn J.F., Montine K.S., Kaye J.A., Breitner J.C. Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. J Alzheimers Dis 2005, 8:359-367.
    • (2005) J Alzheimers Dis , vol.8 , pp. 359-367
    • Montine, T.J.1    Quinn, J.F.2    Montine, K.S.3    Kaye, J.A.4    Breitner, J.C.5
  • 23
    • 0142011171 scopus 로고    scopus 로고
    • Elevated neurofilament levels in neurological diseases
    • Norgren N., Rosengren L., Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003, 987:25-31.
    • (2003) Brain Res , vol.987 , pp. 25-31
    • Norgren, N.1    Rosengren, L.2    Stigbrand, T.3
  • 25
    • 70350061949 scopus 로고    scopus 로고
    • Multimodal techniques for diagnosis and prognosis of Alzheimer's disease
    • Perrin R.J., Fagan A.M., Holtzman D.M. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009, 461:916-922.
    • (2009) Nature , vol.461 , pp. 916-922
    • Perrin, R.J.1    Fagan, A.M.2    Holtzman, D.M.3
  • 27
    • 15944409728 scopus 로고    scopus 로고
    • Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss
    • Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005, 233:183-198.
    • (2005) J Neurol Sci , vol.233 , pp. 183-198
    • Petzold, A.1
  • 29
    • 2342420034 scopus 로고    scopus 로고
    • Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease
    • Pratico D., Sung S. Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J Alzheimers Dis 2004, 6:171-175.
    • (2004) J Alzheimers Dis , vol.6 , pp. 171-175
    • Pratico, D.1    Sung, S.2
  • 37
    • 70349159788 scopus 로고    scopus 로고
    • Validity of cerebrospinal fluid biomarkers as endpoints in early-phase clinical trials for Alzheimer's disease
    • Zhou B., Teramukai S., Yoshimura K., Fukushima M. Validity of cerebrospinal fluid biomarkers as endpoints in early-phase clinical trials for Alzheimer's disease. J Alzheimers Dis 2009, 18:89-102.
    • (2009) J Alzheimers Dis , vol.18 , pp. 89-102
    • Zhou, B.1    Teramukai, S.2    Yoshimura, K.3    Fukushima, M.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.